TY - JOUR T1 - Deep Learning and Risk Score Classification of Mild Cognitive Impairment and Alzheimer’s Disease JF - medRxiv DO - 10.1101/2020.11.09.20226746 SP - 2020.11.09.20226746 AU - Sanjay Nagaraj AU - Tim Q Duong Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/11/25/2020.11.09.20226746.abstract N2 - A large battery of neurocognitive tests are used to detect cognitive impairment and classify early mild cognitive impairment (EMCI), late mild cognitive impairment (LMCI), and Alzheimer’s Disease (AD) from cognitive normal (CN). The goal of this study was to develop a deep learning algorithm to identify a few top neurocognitive tests that can accurately classify these four groups. We also derived a simplified risk-stratification score model for classification. Over 100 variables that included neuropsychological/neurocognitive tests, demographics, genetic factors, and blood biomarkers were collected from 383 EMCI, 644 LMCI, 394 AD patients, and 516 cognitive normal from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database. A neural network algorithm was trained on data split 90% for training and 10% testing. We evaluated five different feature selection methods. Prediction performance used area under the curve (AUC) of the receiver operating characteristic analysis. The five different feature selection methods consistently yielded the top classifiers to be the Clinical Dementia Rating Scale - Sum of Boxes (CDRSB), Delayed total recall (LDELTOTAL), Modified Preclinical Alzheimer Cognitive Composite with Trails test (mPACCtrailsB), the Modified Preclinical Alzheimer Cognitive Composite with Digit test (mPACCdigit), and Mini-Mental State Examination (MMSE). The best classification model yielded an AUC of 0.984, and the simplified risk-stratification score yielded an AUC of 0.962 on the test dataset. The deep-learning algorithm and simplified risk score derived from our deep-learning algorithm accurately classifies EMCI, LMCI, AD and CN patients using a few commonly available neurocognitive tests.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:1) Approval was received by the ADNI data sharing and publications committee (DPC) after registration. 2) No Registration ID or approval code was given. 3) This non-human subject research study was exempt from IRB approval. However, the original data collection procedures were in accordance with an IRB. According to ADNI: "All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.”All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in this study is publicly available on the ADNI (Alzheimer's Disease Neuroimaging Initiative website. Due to the public and de-identified nature of the data, an IRB was not needed. This is non-human subject research. http://adni.loni.usc.edu/ ER -